Side-by-side · Research reference
CerebrolysinvsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED11/65 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
01Mechanism of Action
Parameter
Cerebrolysin
Pancragen
Primary target
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
Yes — preserves physiological glucose-insulin response
Origin
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
—
02Dosage Protocols
Parameter
Cerebrolysin
Pancragen
Standard dose (stroke)
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
—
Lower dose (dementia)
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
—
Duration
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
—
Timing (stroke)
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
—
Adjunct to thrombectomy
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
—
Evidence basis
Phase 3 RCT + observational
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Administration route
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
Cerebrolysin
Pancragen
Injection site reaction
Mild pain, erythema (IM route)
—
Infusion reaction
Rare: flushing, transient hypotension during rapid IV
—
Agitation / Restlessness
Reported in <5% of patients; typically mild, self-limited
—
Serious adverse events
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
—
Hemorrhagic transformation
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
—
Mortality
No increase; meta-analysis RR 0.89 (0.68-1.18)
—
Allergic reaction
Rare; porcine origin theoretically immunogenic but clinically insignificant
—
Seizure risk
Not elevated; safe in epilepsy populations
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Pancragen
—Relative Contraindications
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
Cerebrolysin
Pancragen
1. Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
—
6. Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
—
06Stack Synergy
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery
Pancragen
— no documented stacks